NEW YORK (GenomeWeb News) – Luminex and Becton Dickinson’s Diagnostics-TriPath division have struck a development and supply agreement for biomarker-based cancer tests, Luminex said yesterday.
 
BD Diagnostics-TriPath will use Luminex’s multiplexing xMAP Technology, which allows multiple, simultaneous tests to be conducted using one sample, to develop diagnostic tests for certain cancers that BD will market.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.